Table 1 Characteristics of the included studies
From: Tolvaptan for water retention in heart failure: a systematic review
Article IDs | Number of Included Studies | Number of Included participants | Treatment Group | Control Group | Tools for quality evaluation | Outcome measures |
|---|---|---|---|---|---|---|
Yang CJ 2015(CN) [23] | 8 | 13453 | Tolvaptan | placebo | Jadad scale | ①③ |
Wang CB 2017(CN) [15] | 6 | 746 | Tolvaptan | placebo or active controls | Cochrane risk of bias tool | ①③④ |
Wu MY 2019(CN) [16] | 12 | 5793 | Tolvaptan | Placebo | Cochrane risk of bias tool | ①②③④ |
Ma G 2018(CN) [17] | 7 | 937 | Tolvaptan Add-on therapy | placebo or active controls | Cochrane risk of bias tool | ①③④ |
Xiong B 2015(CN) [18] | 10 | 5574 | Tolvaptan | placebo or active controls | Cochrane risk of bias tool | ①③④ |
Huang WI 2018(CN) [22] | 6 | 669 | Tolvaptan | placebo or active controls | Jadad scale | ①②④ |
Kinugawa K 2018(JP) [19] | 14 | 5991 | Tolvaptan Add-on therapy | placebo or active controls | Cochrane risk of bias tool | ①②③ |
Luo XD 2020(CN) [21] | 12 | 5577 | Tolvaptan Add-on therapy | placebo or active controls | Cochrane risk of bias tool | ①②③④ |
Alskaf.E.E 2016(the UK) [20] | 8 | 5385 | Tolvaptan | Placebo | Cochrane risk of bias tool | ①②③④ |